Selected article for: "case definition and cross sectional study"
Author: Guerra, Ivan; Algaba, Alicia; Jiménez, Laura; Mar Aller, Mª; Garza, Daniel; Bonillo, Daniel; Molina Esteban, Laura María; Bermejo, Fernando
Title: Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain
  • Cord-id: 27y09gob
  • Document date: 2020_8_24
    • ID: 27y09gob
    Snippet: BACKGROUND: There are scarce data about SARS-CoV-2 infection in patients with inflammatory bowel disease (IBD). Our aim was to analyze the incidence, clinical presentation, and severity of SARS-CoV-2 infection in patients with IBD. METHODS: This is a cross-sectional, observational study. We contacted all the patients being treated at our IBD unit to identify those patients with suspected or confirmed SARS-CoV-2 infection, following the World Health Organization case definition. Data were obtaine
    Document: BACKGROUND: There are scarce data about SARS-CoV-2 infection in patients with inflammatory bowel disease (IBD). Our aim was to analyze the incidence, clinical presentation, and severity of SARS-CoV-2 infection in patients with IBD. METHODS: This is a cross-sectional, observational study. We contacted all the patients being treated at our IBD unit to identify those patients with suspected or confirmed SARS-CoV-2 infection, following the World Health Organization case definition. Data were obtained by patient electronical medical records and by phone interview. RESULTS: Eighty-two of 805 patients with IBD (10.2%; 95% confidence interval [CI], 8.3-12.5) were diagnosed as having confirmed (28 patients, 3.5%; 95% CI, 2.4-5.0) or suspected (54 patients, 6.7%) infection. Patient age was 46 ± 14 years, 44 patients were female (53.7%), 17.3% were smokers, 51.2% had Crohn disease (CD), and 39.0% had comorbidities. Digestive symptoms were reported in 41 patients (50.0%), with diarrhea as the most common (42.7%). One patient (1.2%) was diagnosed with IBD flare-up during SARS-CoV-2 infection. Twenty-two patients (26.8%) temporarily withdrew from their IBD treatment because of COVID-19. Most of the patients had mild disease (79.3%), and 1 patient died (1.2%). In the multivariate analysis, the presence of dyspnea was associated with moderate to severe infection (odds ratio, 5.3; 95% CI, 1.6-17.7; P = 0.01) and myalgias (odds ratio, 4.8; 95% CI, 1.3-17.9; P = 0.02) were related to a milder clinical course. Immunosuppression was not related to severity. CONCLUSIONS: SARS-CoV-2 infection in patients with IBD is not rare. Dyspnea is associated with a more severe infection. Therapy for IBD, including immunomodulators and biologic therapy, is not related to a greater severity of COVID-19, and SARS-CoV-2 infections do not appear to be related to IBD flare-ups.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • abdominal pain and logistic regression model: 1, 2
    • abdominal pain and low moderate: 1, 2
    • abdominal pain and lung disease: 1, 2, 3, 4, 5, 6, 7
    • active disease and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7
    • active disease and logistic regression model: 1, 2
    • active disease and low moderate: 1, 2
    • active disease and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active disease risk and acute respiratory distress syndrome: 1
    • active disease risk and lung disease: 1
    • acute respiratory distress syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory distress syndrome and long term evolution: 1
    • acute respiratory distress syndrome and low moderate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory distress syndrome and low suspicion: 1
    • acute respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adalimumab golimumab and lung disease: 1, 2
    • adalimumab golimumab infliximab and lung disease: 1
    • logistic regression model and low moderate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • logistic regression model and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15